Details
Stereochemistry | RACEMIC |
Molecular Formula | C12H17NO3 |
Molecular Weight | 223.2683 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=C(NC(=O)CC(C)O)C=C1
InChI
InChIKey=LIAWQASKBFCRNR-UHFFFAOYSA-N
InChI=1S/C12H17NO3/c1-3-16-11-6-4-10(5-7-11)13-12(15)8-9(2)14/h4-7,9,14H,3,8H2,1-2H3,(H,13,15)
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.waters.com/webassets/cms/library/docs/720004141en.pdf | http://www.waters.com/webassets/cms/library/docs/720005475en.pdf | http://journals.sagepub.com/doi/abs/10.1177/009286150103500134
Curator's Comment: Description was created based on several sources, including
http://www.waters.com/webassets/cms/library/docs/720004141en.pdf | http://www.waters.com/webassets/cms/library/docs/720005475en.pdf | http://journals.sagepub.com/doi/abs/10.1177/009286150103500134
Bucetin (3-hydroxy-p-butyrophenetidide) is an antipyretic analgesic drug with cancerogenic potential. Bucetin was withdrawn from the market due to renal toxicity. The compound has the chiral center. Pharmacological activity of enantiomers is unknown. The racemic mixture is used as a model compound to demostrate effectivity of the chiral supercritical fluid chromatography purification.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Betadid Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3479641 |
Primary | Betadid Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5583134
Curator's Comment: The tablet contains bucetin 100 mg, ethoxybenzamide 100 mg, Al-acetylsalicylate 180 mg (https://www.jstage.jst.go.jp/article/cpb1958/15/7/15_7_1002/_pdf)
The tablet contains bucetin 100 mg. The tablets are given to male adults with 200 ml of water on a fasting stomach.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5709240
Curator's Comment: https://www.jstage.jst.go.jp/article/cpb1958/33/7/33_7_2877/_pdf
Bucetin was found to be mutagenic to Salmonella typhimurum TA100 in the presence of liver 9000g supernatant fraction (S9) prepared from polychlorinated biphenyl (PCB)-treated hamsters and a reduced NADPH-generating system.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02BE74
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
||
|
WHO-VATC |
QN02BE54
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
||
|
WHO-ATC |
N02BE54
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
||
|
WHO-VATC |
QN02BE04
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
||
|
NCI_THESAURUS |
C241
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
||
|
WHO-ATC |
N02BE04
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
||
|
WHO-VATC |
QN02BE74
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1283
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
214-109-8
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
C72112
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
759243
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
413
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
1083-57-4
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
SUB05942MIG
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
Bucetin
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
DTXSID6020721
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
14130
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
320045
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
DB13278
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
100000085843
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL1697856
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
m2737
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
6M7CVQ8PF8
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY | |||
|
C023637
Created by
admin on Fri Dec 15 16:30:22 GMT 2023 , Edited by admin on Fri Dec 15 16:30:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY